Recent Updates
Recently added Catalysts
MDGL Positive Sentiment

Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference

Wednesday, October 2, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) has announced its participation in the upcoming H.C. Wainwright 8th Annual MASH Virtual Investor Conference scheduled for October 7, 2024. The event will feature a fireside chat that will be webcast live, enhancing investor engagement. Madrigal is known for its innovative treatments targeting nonalcoholic steatohepatitis (NASH), addressing a critical unmet need in liver diseases.
Price reaction · baseline $209.33 (2024-10-01 close) · hit after-hours · clean, no other MDGL news in the window
day 0 close
-0.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Madrigal Pharmaceuticals is actively engaging with investors at a prominent conference.
  • The company is focusing on a significant medical need with its therapies for NASH.
  • The live webcast of the fireside chat provides transparency and accessibility for investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+125%
120-day peak, hindsight
Typical move
4.2%
average across 7 past catalysts
Cash runway
~45 mo
Minimal dilution risk
Lead asset
Resmetirom
Phase 3 · Non-Alcoholic Fatty Liver Disease

Full Press Release Details

CONSHOHOCKEN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced the company will participate in a fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Investor Conference at 2:00 P.M. ET on Monday, Oct. 7, 2024.
The fireside chat will be webcast live and may be accessed here or by visiting Madrigal’s website’s Investor Relations Events page. A replay of the webcast will be available after the event.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.

Frequently Asked Questions

When is Madrigal Pharmaceuticals' fireside chat?

The fireside chat is scheduled for October 7, 2024, at 2:00 P.M. ET.

How can I access the fireside chat webcast?

The webcast will be accessible via Madrigal's website or directly here.

What disease does Madrigal Pharmaceuticals focus on?

Madrigal Pharmaceuticals is focused on nonalcoholic steatohepatitis (NASH).

What is Madrigal’s key medication for NASH?

Madrigal’s key medication for NASH is Rezdiffra (resmetirom).

What type of drug is Rezdiffra?

Rezdiffra is a once-daily oral liver-directed THR-β agonist.

ShareAdd on Google
Tags: MDGL Viatris Investor Conferences Healthcare Madrigal Pharmaceuticals NASH H.C. Wainwright investor conference
Last updated: Oct 2, 2024

Biotech snapshot

Cash runway
$839M liquidity · $19M/mo burn
~45 mo
Minimal dilution risk
Lead asset
ResmetiromPhase 3
Non-Alcoholic Fatty Liver Disease →

Catalyst track record

+125%
best trade around MDGL's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for MDGL.

See every catalyst's timing & PoA →